This study is testing a drug called atumelnant in children aged 1 to 17 years old who have classic congenital adrenal hyperplasia (CAH), a condition where the adrenal glands don't make enough of certain hormones. The main goals are to see how safe and effective atumelnant is, and how the body uses and reacts to the drug. Researchers will measure changes in a hormone called androstenedione (A4) and how much steroid medicine (glucocorticoid) participants need. Some participants will receive atumelnant, while others will receive a placebo (an inactive substance that looks like the drug). The study aims to enroll about 153 participants.

Study design

This is a Phase 2/3 study with an open-label extension. It includes a double-blind, randomized, placebo-controlled part, meaning some participants will receive atumelnant and others a placebo, and neither you nor your doctor will know which you are receiving.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Some participants may be followed for up to 260 weeks (about 5 years) to observe changes in serum early morning A4 over time.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.